About
Apim Therapeutics AS is a clinical-stage biotech company developing peptide therapeutics targeting PCNA-dependent cellular stress response pathways to overcome cancer treatment resistance, with lead candidate ATX-101 undergoing Phase I/II clinical trials in cancers including ovarian cancer and soft tissue sarcoma.
Explore Apim Therapeutics AS's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.